IL247920B - The compound (r)-2-(4-((2- ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy) acetic acid or a salt thereof for use in treating an intrahepatic cholestatic disease - Google Patents
The compound (r)-2-(4-((2- ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy) acetic acid or a salt thereof for use in treating an intrahepatic cholestatic diseaseInfo
- Publication number
- IL247920B IL247920B IL247920A IL24792016A IL247920B IL 247920 B IL247920 B IL 247920B IL 247920 A IL247920 A IL 247920A IL 24792016 A IL24792016 A IL 24792016A IL 247920 B IL247920 B IL 247920B
- Authority
- IL
- Israel
- Prior art keywords
- methylphenoxy
- thio
- phenoxy
- trifluoromethyl
- ethoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968037P | 2014-03-20 | 2014-03-20 | |
| PCT/US2015/021502 WO2015143178A1 (en) | 2014-03-20 | 2015-03-19 | Treatment of intrahepatic cholestatic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL247920B true IL247920B (en) | 2019-03-31 |
Family
ID=52808186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL247920A IL247920B (en) | 2014-03-20 | 2016-09-19 | The compound (r)-2-(4-((2- ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy) acetic acid or a salt thereof for use in treating an intrahepatic cholestatic disease |
Country Status (32)
| Country | Link |
|---|---|
| US (5) | US9486428B2 (https=) |
| EP (1) | EP3119384B1 (https=) |
| JP (1) | JP6568577B2 (https=) |
| KR (1) | KR102000332B1 (https=) |
| CN (1) | CN106102734B (https=) |
| AU (1) | AU2015231232B2 (https=) |
| BR (1) | BR112016020260A8 (https=) |
| CA (1) | CA2941401C (https=) |
| CL (1) | CL2016002338A1 (https=) |
| CY (1) | CY1120927T1 (https=) |
| DK (1) | DK3119384T3 (https=) |
| EA (1) | EA032358B1 (https=) |
| ES (1) | ES2701094T3 (https=) |
| FI (1) | FIC20253004I1 (https=) |
| FR (1) | FR25C1031I2 (https=) |
| HR (1) | HRP20181914T1 (https=) |
| HU (2) | HUE041733T2 (https=) |
| IL (1) | IL247920B (https=) |
| LT (2) | LT3119384T (https=) |
| MX (1) | MX367478B (https=) |
| NL (1) | NL301338I2 (https=) |
| NO (1) | NO2025035I1 (https=) |
| NZ (1) | NZ724057A (https=) |
| PH (1) | PH12016501769B1 (https=) |
| PL (1) | PL3119384T3 (https=) |
| PT (1) | PT3119384T (https=) |
| RS (1) | RS57970B1 (https=) |
| SI (1) | SI3119384T1 (https=) |
| SM (1) | SMT201800690T1 (https=) |
| UA (1) | UA120756C2 (https=) |
| WO (1) | WO2015143178A1 (https=) |
| ZA (1) | ZA201606043B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2740874C (en) * | 2008-10-17 | 2018-02-27 | Metabolex, Inc. | Use of ppar.gamma.agonists to reduce small dense ldl particles |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| KR102374499B1 (ko) | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| DK3973959T3 (da) | 2017-09-26 | 2025-01-20 | Cymabay Therapeutics Inc | Behandling af kolestatisk kløe med seladelpar |
| EP3880187A1 (en) * | 2018-11-16 | 2021-09-22 | CymaBay Therapeutics, Inc. | Treatment of obesity and its complications |
| JP7731868B2 (ja) | 2019-08-02 | 2025-09-01 | エースロット，インコーポレイテッド | ＴＤＰ－４３、α－シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法 |
| US20210145774A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of alcoholic liver disease |
| WO2021097034A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases |
| US20220241228A1 (en) | 2021-02-01 | 2022-08-04 | Cymabay Therapeutics, Inc. | Treatment of cholangiopathies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| WO1996027606A1 (en) | 1995-03-06 | 1996-09-12 | Isis Pharmaceuticals, Inc. | Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom |
| NZ331217A (en) | 1996-02-14 | 2000-02-28 | Novartis Ag | Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7981915B2 (en) * | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
| WO2005042478A2 (en) | 2003-09-19 | 2005-05-12 | Janssen Pharmaceutica, N.V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| KR101494067B1 (ko) | 2004-03-05 | 2015-02-16 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법 |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| CA2740874C (en) | 2008-10-17 | 2018-02-27 | Metabolex, Inc. | Use of ppar.gamma.agonists to reduce small dense ldl particles |
| NZ602125A (en) | 2010-03-30 | 2014-01-31 | Novartis Ag | Uses of dgat1 inhibitors |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| HK1224186A1 (zh) | 2013-11-20 | 2017-08-18 | Cymabay Therapeutics, Inc. | 纯阖家族型高胆固醇血症的治疗 |
| US20160279085A1 (en) | 2013-11-20 | 2016-09-29 | Cymabay Therapeutics, Inc. | Treatment of Severe Hyperlipidemia |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| KR102374499B1 (ko) | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| EP3160458A1 (en) | 2014-06-26 | 2017-05-03 | Cymabay Therapeutics, Inc. | Treatment of severe hypertriglyceridemia |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| DK3973959T3 (da) | 2017-09-26 | 2025-01-20 | Cymabay Therapeutics Inc | Behandling af kolestatisk kløe med seladelpar |
| EP3880187A1 (en) | 2018-11-16 | 2021-09-22 | CymaBay Therapeutics, Inc. | Treatment of obesity and its complications |
| EP3880185A1 (en) | 2018-11-16 | 2021-09-22 | CymaBay Therapeutics, Inc. | Combination treatment of nafld and nash |
-
2015
- 2015-03-19 RS RS20181363A patent/RS57970B1/sr unknown
- 2015-03-19 EP EP15714132.6A patent/EP3119384B1/en active Active
- 2015-03-19 CA CA2941401A patent/CA2941401C/en active Active
- 2015-03-19 SI SI201530455T patent/SI3119384T1/sl unknown
- 2015-03-19 HR HRP20181914TT patent/HRP20181914T1/hr unknown
- 2015-03-19 AU AU2015231232A patent/AU2015231232B2/en active Active
- 2015-03-19 BR BR112016020260A patent/BR112016020260A8/pt not_active Application Discontinuation
- 2015-03-19 ES ES15714132T patent/ES2701094T3/es active Active
- 2015-03-19 JP JP2017501116A patent/JP6568577B2/ja active Active
- 2015-03-19 LT LTEP15714132.6T patent/LT3119384T/lt unknown
- 2015-03-19 PT PT15714132T patent/PT3119384T/pt unknown
- 2015-03-19 SM SM20180690T patent/SMT201800690T1/it unknown
- 2015-03-19 KR KR1020167025636A patent/KR102000332B1/ko active Active
- 2015-03-19 HU HUE15714132A patent/HUE041733T2/hu unknown
- 2015-03-19 US US14/663,027 patent/US9486428B2/en active Active
- 2015-03-19 WO PCT/US2015/021502 patent/WO2015143178A1/en not_active Ceased
- 2015-03-19 UA UAA201609525A patent/UA120756C2/uk unknown
- 2015-03-19 CN CN201580014506.0A patent/CN106102734B/zh active Active
- 2015-03-19 EA EA201691887A patent/EA032358B1/ru active IP Right Revival
- 2015-03-19 NZ NZ724057A patent/NZ724057A/en unknown
- 2015-03-19 PL PL15714132T patent/PL3119384T3/pl unknown
- 2015-03-19 MX MX2016012203A patent/MX367478B/es active IP Right Grant
- 2015-03-19 DK DK15714132.6T patent/DK3119384T3/en active
-
2016
- 2016-08-31 ZA ZA2016/06043A patent/ZA201606043B/en unknown
- 2016-09-08 PH PH12016501769A patent/PH12016501769B1/en unknown
- 2016-09-15 CL CL2016002338A patent/CL2016002338A1/es unknown
- 2016-09-19 IL IL247920A patent/IL247920B/en active IP Right Grant
- 2016-09-21 US US15/271,460 patent/US9808436B2/en active Active
-
2017
- 2017-09-29 US US15/720,849 patent/US10220011B2/en active Active
-
2018
- 2018-11-28 CY CY181101264T patent/CY1120927T1/el unknown
- 2018-12-17 US US16/222,325 patent/US10828273B2/en active Active
-
2020
- 2020-10-03 US US17/062,545 patent/US11406611B2/en active Active
-
2025
- 2025-07-31 FI FIC20253004C patent/FIC20253004I1/fi unknown
- 2025-07-31 LT LTPA2025529C patent/LTPA2025529I1/lt unknown
- 2025-08-01 NO NO2025035C patent/NO2025035I1/no unknown
- 2025-08-05 FR FR25C1031C patent/FR25C1031I2/fr active Active
- 2025-08-13 HU HUS2500033C patent/HUS2500033I1/hu unknown
- 2025-08-13 NL NL301338C patent/NL301338I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247920B (en) | The compound (r)-2-(4-((2- ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy) acetic acid or a salt thereof for use in treating an intrahepatic cholestatic disease | |
| CY2024035I2 (el) | Συνθεσεις αντισωματων για τη θεραπεια ογκων | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| EP3517528A4 (en) | ACID ADDITION SALT OF BENZIMIDAZOLE DERIVATIVE | |
| ZA201700629B (en) | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof | |
| IL286592B (en) | Amino acid compounds for the treatment of liver disease | |
| NZ724740A (en) | Treatment of nafld and nash | |
| CO6890103A2 (es) | Compuestos sustituidos fungicidas de 2-[2-halogenalquil-4-(fenoxi)-fenil]-1-[1,2,4]triazol-1-il-etanol | |
| HUE047666T2 (hu) | Eljárás 2-[4-(4-Klórfenoxi)-2-(trifluormetil)fenil]-1-(1,2,4-triazol-1-il)-2-propanol elõállítására | |
| EP3422155A4 (en) | OBJECT CONTROLLER | |
| IL245748A0 (en) | (r)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-(methylphenoxy)acetic acid for use in the treatment of homozygous familial hypercholesterolemia | |
| EP3473614A4 (en) | SULFONIC ACID ESTER COMPOUND AND USE THEREOF | |
| EP3473613A4 (en) | SULFONIC ACID ESTER COMPOUND AND USE THEREOF | |
| DK3233843T3 (da) | Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere | |
| IL254653A0 (en) | Methods of treating liver disease using indane acetic acid history | |
| IL255625B (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| EP2975022A4 (en) | NOVEL HYDROXAMINE ACID DERIVATIVE OR SALT THEREOF | |
| IL263372A (en) | Treatment of intrahepatic cholestatic diseases | |
| LU92414B1 (fr) | Compostion cosmétique anhydre applicable sur les ongles | |
| IL274747A (en) | FXR agonists for the treatment of liver diseases | |
| DK3362056T3 (da) | Aminothiolesterforbindelser eller farmaceutisk acceptable salte deraf, til anvendelse ved behandling af cancer | |
| EP3390346A4 (en) | COMPOSITIONS AND METHODS RELATING TO SALT SALT OF HERBIC CARBOXYLIC ACIDS | |
| IT1403094B1 (it) | Procedimento per la preparazione di fesoterodina o un suo sale | |
| HUE052088T2 (hu) | Neridronsav vagy sójának alkalmazása osteoarthrosis kezelésére | |
| ZA201706986B (en) | Compositions for the treatment of kidney and/or liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |